Compare GSK plc (GSK) vs Simon Property Group Inc (SPG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Simon Property Group Inc — how do they compare? GSK plc trades at $52.66 (market cap $101.34B), while Simon Property Group Inc trades at $227.31 (market cap $72.00B). The key difference: GSK plc is the larger of the two by market cap, and Simon Property Group Inc pays the higher dividend (3.96%). Which is the better fit depends on your goals.
| GSK | SPG | |
|---|---|---|
Market Cap | $101.34B | $72.00B |
Sector | Health | Real Estate |
52-Week High | $61.18 | $227.56 |
52-Week Low | $36.20 | $160.68 |
Enterprise Value | $121.95B | $100.48B |
Dividend Yield | 3.49% | 3.96% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK's stock trades at $51.25, down 1.99% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 17.78% net margin and 36.42% ROE, supported by a consistent earnings beat history. Recent positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline progress. Valuation appears reasonable with a P/E of 13.71 and EV/EBITDA of 9.16.
The outlook balances a solid core business and promising oncology pipeline against a mixed analyst consensus and near-term cash flow pressures. Key opportunities lie in execution of new drug launches and the upcoming CEO strategy update, while risks include clinical trial setbacks, competitive pressures, and integration of potential acquisitions like Nuvalent.
Simon Property Group (SPG) trades at $221.28, up 0.82% with a bearish technical signal despite recent earnings beats. The REIT shows strong fundamentals with $4.63B net income (72.7% margin) and robust cash flow, though net cash flow turned negative in 2025. Recent news highlights strong leasing activity but concerns about valuation and debt levels. The stock trades above the consensus price target of $214.40 with mixed analyst sentiment (40.5% buy, 54.1% hold).
SPG offers quality real estate exposure with premium mall assets and consistent dividend payments, but faces headwinds from e-commerce competition and high leverage. Current valuation appears full with limited margin of safety. The upcoming Q2 2026 earnings report on July 1 will be crucial for confirming growth trajectory amid mixed technical indicators and cautious Wall Street positioning.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Simon Property Group Inc
Simon Property Group is the second- largest real estate investment trust in the United States. Its portfolio includes an interest in 207 properties: 119 traditional malls, 69 premium outlets, 14 Mills centers (a combination of a traditional mall, outlet center, and big-box retailers), six lifestyle centers, and five other retail properties. Simon's portfolio averaged $693 in sales per square foot over the 12 months prior to the pandemic. The company also owns a 21% interest in Klepierre, a European retail company with investments in shopping centers in 16 countries, and joint venture interests in 33 premium outlets across 11 countries.
Read more on SPG →
